Lyra Therapeutics Past Earnings Performance
Past criteria checks 0/6
Lyra Therapeutics's earnings have been declining at an average annual rate of -32.5%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 62.9% per year.
Key information
-32.5%
Earnings growth rate
97.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 62.9% |
| Return on equity | -88.9% |
| Net Margin | -4,099.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11
Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Revenue & Expenses BreakdownBeta
How Lyra Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2 | -69 | 20 | 6 |
| 31 Dec 23 | 2 | -63 | 19 | 0 |
| 30 Sep 23 | 1 | -62 | 19 | 0 |
| 30 Jun 23 | 1 | -61 | 20 | 0 |
| 31 Mar 23 | 1 | -60 | 21 | 0 |
| 31 Dec 22 | 1 | -55 | 18 | 0 |
| 30 Sep 22 | 2 | -55 | 18 | 0 |
| 30 Jun 22 | 1 | -51 | 17 | 0 |
| 31 Mar 22 | 1 | -48 | 16 | 0 |
| 31 Dec 21 | 0 | -44 | 14 | 0 |
| 30 Sep 21 | 0 | -37 | 16 | 0 |
| 30 Jun 21 | 0 | -32 | 14 | -5 |
| 31 Mar 21 | 0 | -26 | 11 | -3 |
| 31 Dec 20 | 0 | -22 | 10 | 0 |
| 30 Sep 20 | 0 | -20 | 8 | 3 |
| 30 Jun 20 | 0 | -18 | 6 | 11 |
| 31 Mar 20 | 0 | -17 | 5 | 12 |
| 31 Dec 19 | 0 | -17 | 4 | 12 |
| 31 Dec 18 | 1 | -6 | 4 | 5 |
Quality Earnings: LYRA is currently unprofitable.
Growing Profit Margin: LYRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LYRA is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.
Accelerating Growth: Unable to compare LYRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LYRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: LYRA has a negative Return on Equity (-88.87%), as it is currently unprofitable.